- Amneal Pharmaceuticals, Inc. - Amneal Receives U. S. FDA . . .
Amneal Receives U S FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
- Best New Migraine Medications and Treatments — Migraine Again
The past several years have seen more advancements in migraine-specific treatments than in the past three decades Let that sink in Since 2018, several new therapies have emerged to both treat migraine and or prevent migraine attacks And the hits keep coming: During 2024 to 2025 alone, four new treatments were approved
- New Treatments for Migraines: What Actually Works in 2025?
What are the most effective new treatments for migraines in 2025? The most effective new treatments include CGRP-targeted therapies such as oral gepants (rimegepant, atogepant), monoclonal antibodies (eptinezumab, erenumab, fremanezumab, galcanezumab), and non-drug devices like Nerivio and Relivion MG
- FDA Approves Brekiya (dihydroergotamine mesylate) Injection . . .
All News Consumer Pro New Drugs Pipeline Clinical Trials FDA Alerts FDA Approves Brekiya FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults BRIDGEWATER, N J , May 15, 2025 -- Amneal Pharmaceuticals, Inc (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U S Food and Drug Administration (FDA
- FDA Approves Brekiya, First and Only DHE Autoinjector, for . . .
The FDA approved a dihydroergotamine (DHE) mesylate injection (Brekiya; Amneal Pharmaceuticals), the first and only DHE autoinjector for acute treatment of migraine with or without aura and cluster headaches in adult patients DHE is the same medication used in hospitals and emergency rooms (ERs), and with an approved autoinjector, patients are able to receive the medication in a ready-to-use
|